Publications dans lesquelles il/elle collabore avec CRISTINA JIMÉNEZ LUNA (28)

2023

  1. Combining Olaparib and Ascorbic Acid on Nanoparticles to Enhance the Drug Toxic Effects in Pancreatic Cancer

    International journal of nanomedicine, Vol. 18, pp. 5075-5093

  2. Curso de anatomía de tórax y abdomen para estudiantes de Biociencias

    Innovación docente e investigación en educación: nuevas tendencias para el cambio en la enseñanza superior (Dykinson), pp. 233-240

  3. Evaluating Metabolite-Based Biomarkers for Early Diagnosis of Pancreatic Cancer: A Systematic Review

    Metabolites, Vol. 13, Núm. 7

  4. Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis

    NMR in Biomedicine, Vol. 36, Núm. 9

2022

  1. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine

    Biomedicine and Pharmacotherapy, Vol. 155

2021

  1. Circulating ptgs2, jag1, gucy2c and pgf mrna in peripheral blood and serum as potential biomarkers for patients with metastatic colon cancer

    Journal of Clinical Medicine, Vol. 10, Núm. 11

  2. Impact of the epigenetically regulated hoxa-5 gene in neural differentiation from human adipose-derived stem cells

    Biology, Vol. 10, Núm. 8

  3. Liquid biopsy approach to pancreatic cancer

    World Journal of Gastrointestinal Oncology, Vol. 13, Núm. 10, pp. 1263-1287

  4. Temozolomide: An updated overview of resistance mechanisms, nanotechnology advances and clinical applications

    Current Neuropharmacology, Vol. 19, Núm. 4, pp. 513-537

  5. Untargeted metabolomics for the diagnosis of exocrine pancreatic insufficiency in chronic pancreatitis

    Medicina (Lithuania), Vol. 57, Núm. 9

2020

  1. Differentiation of human mesenchymal stem cells towards neuronal lineage: Clinical trials in nervous system disorders

    Biomolecules and Therapeutics, Vol. 28, Núm. 1, pp. 34-44

  2. Discovery of pancreatic adenocarcinoma biomarkers by untargeted metabolomics

    Cancers, Vol. 12, Núm. 4

  3. MMR-proficient and MMR-deficient colorectal cancer cells: 5-Fluorouracil treatment response and correlation to CD133 and MGMT expression

    Journal of Biosciences, Vol. 45, Núm. 1

  4. Nanoparticles in Colorectal Cancer Therapy: Latest In Vivo Assays, Clinical Trials, and Patents

    AAPS PharmSciTech, Vol. 21, Núm. 5

  5. Novel biomarkers to distinguish between type 3c and type 2 diabetes mellitus by untargeted metabolomics

    Metabolites, Vol. 10, Núm. 11, pp. 1-12

  6. Role of exocrine and endocrine insufficiency in the management of patients with chronic pancreatitis

    Journal of Clinical Medicine, Vol. 9, Núm. 6, pp. 1-12

  7. State of the art in exocrine pancreatic insufficiency

    Medicina (Lithuania), Vol. 56, Núm. 10, pp. 1-10

2019

  1. The challenge of drug resistance in pancreatic ductal adenocarcinoma: a current overview

    Cancer Biology and Medicine, Vol. 16, Núm. 4, pp. 688-699

  2. Untargeted LC-HRMS-based metabolomics to identify novel biomarkers of metastatic colorectal cancer

    Scientific Reports, Vol. 9, Núm. 1

2018

  1. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers

    PLoS ONE, Vol. 13, Núm. 4